Bibliographic Details
| Title: |
Ajuste de la cifra de hemoglobina glucosilada para el diagnóstico de diabetes mellitus en México. |
| Alternate Title: |
Adjustment of the glycated hemoglobin value to diagnose diabetes mellitus in Mexico. |
| Authors: |
Félix-Bulman, Jorge Andrés1 jaf84@hotmail.com, Gómez-Gómez, B.1, Ramírez-Angulo, C.2, Toriello-Martínez, S.2, Fragoso-González, A.3, Díaz-Greene, Enrique Juan4, Rodríguez-Weber, Federico Leopoldo5 |
| Source: |
Medicina Interna de México. mar/apr2018, Vol. 34 Issue 2, p196-203. 8p. 3 Charts, 1 Graph. |
| Abstract (English): |
BACKGROUND: Nowadays, the American Diabetes Association (ADA) recognizes the use of three tests for the diagnosis of diabe tes mellitus, including the determination of glycated hemoglobin (HbA1c). OBJECTIVE: To evaluate if the established value of 6.5% of glycated hemoglobin for the diagnosis of diabetes mellitus is applicable to the Mexican population. MATERIAL AND METHOD: A descriptive, transversal and analytic study was done in October 2016 in persons that were subjected to a capillary test for HbA1c and serum glucose. RESULTS: There were included 388 subjects in whom it was determined that the age and the sex did not influence on the obtaining of a determinate level of HbA1c. Capillary HbA1c test tended to diagnose a greater number of cases of prediabetes (170 vs 63) and diabetes (27 vs 13) compared with serum glucose test, with a difference in the number of healthy persons between the two groups of 121 (191 healthy persons with HbA1C and 312 healthy persons with serum glucose); however, both variables shared a 90.2% of similarity (p < 0.001). It was obtained a new threshold of HbA1C for the diagnosis of diabetes of 6.65% (with sensitivity and specificity of 76% and 97%, respectively). CONCLUSION: With the new cutoff value the incidence of cases of diabetes decreased in the HbA1c group, with a reduction of 7% to 4.9% (27 to 19 cases). [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): |
ANTECEDENTES: En la actualidad la Asociación Americana de Diabetes (ADA) acepta el uso de tres pruebas para el diagnóstico de diabetes mellitus, que incluyen la determinación de hemoglobina glucosilada (HbA1c). OBJETIVO: Evaluar si la cifra establecida de HbA1c de 6.5% para el diagnóstico de diabetes mellitus es válida para la población mexicana. MATERIAL Y MÉTODO: Estudio descriptivo, transversal y analítico en el que en octubre de 2016 se incluyeron personas en quienes se determinó HbA1c en sangre capilar y glucemia en sangre venosa. RESULTADOS: Se incluyeron 388 pacientes. Se determinó que ni la edad ni el sexo predisponen a la obtención de una cifra determinada de HbA1c. La prueba de HbA1c capilar tendió a diagnosticar mayor número de casos de prediabetes (170 vs 63) y diabetes (27 vs 13) en comparación con la prueba de glucosa sérica, con diferencia en el número de personas sanas entre ambos grupos de 121 (191 personas sanas con HbA1c y 312 personas sanas con glucosa sérica); sin embargo, ambas variables compartieron 90.2% de similitud (p < 0.001). Se obtuvo un nuevo nivel de corte de HbA1c para el diagnóstico de diabetes de 6.65% (con sensibilidad y especificidad de 76 y 97%, respectivamente). CONCLUSIÓN: Con el nuevo punto de corte disminuyó la incidencia de casos de diabetes en el grupo de HbA1c, con reducción de 7 a 4.9% (27 a 19 casos). [ABSTRACT FROM AUTHOR] |
|
Copyright of Medicina Interna de México is the property of Colegio de Medicina Interna de Mexico and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
MedicLatina |
